Calcium dobesilate drug reagents, through the inhibition of vasoactive substances (histamine, 5 - hydroxytryptamine, bradykinin, hyaluronidase, prostate gonadotropin) caused by the high permeability of the role, thus improving the basement membrane collagen bio- synthesis. A variety of diseases caused by microvascular circulation disorder (capillary circulation disorder) have effect.
Drug Introduction【English name】 Doxium tablets
[category] ENT medicine.
[Pharmacology] calcium dobesilate capsules (Calcium Dobesilate): Yes - the kinds of oral vascular protective agent on the DR, "three" factors significantly inhibit and reverse the effects. It can reduce the high permeability of the capillaries, reducing blood viscosity, reduce high platelet activity, thereby reducing the retinal exudation, bleeding, reduce capillary hemangioma. Studies have shown that after the diagnosis of diabetes has not happened yet clinically visible retinopathy when preventive medication, the prognosis is better on the DR. The therapeutic effect of calcium dobesilate capsules (calcium dobesilate) is multifaceted. By reducing capillary permeability, stability of the blood retinal barrier, can reduce retinal blood extravasation, keep the blood of normal dilution. Reduce the plasma protein molecules and reduce red blood cell rigidity and cohesion, can improve blood circulation: decrease platelet cohesion, prevents ischemia occurred. calcium dobesilate capsules (Calcium Dobesilate) because of its multifaceted role to reduce intraocular pressure: to increase blood flow to reduce retinal bleeding and high blood viscosity, improve the status of the retina of the DR and glaucoma patients, expand their horizons. Its outstanding clinical results and toxic side effects, long-term use for the prevention and treatment of DR and glaucoma patients intraocular lesions.
Indications diabetic retinal lesions.
consumption usage: oral subclinical retinopathy or preventive medication, daily 500mg in 1 or 2 times taking; non-proliferative retinopathy or occult retinopathy daily 750 ~ 1500mg, analysis 2 to 3 times daily; proliferative retinopathy, daily 1500 to 2000mg, divided into 3 to 4 times daily. The mild treatment for one to three months in the disease course of 6 to 12 months, severe course of treatment for 1 to 2 years. DR treatment with calcium dobesilate, 1500mg/day, three times a day orally.
【Note】 This product is less adverse reactions, mainly gastrointestinal discomfort; followed by fatigue, weakness, drowsiness, dizziness, headache; allergic skin reaction; occasional fever, sweating, facial red heat, heart discomfort. Gastrointestinal dysfunction, or who are allergic to disable.
[Specifications】 capsules: Each capsule 500mg, pack of 60. Xi'an lijun pharmaceutical AG, packing 500 mg of X30 tablets.
Drug detailed conditions: calcium dobesilate
GMT+8, 2014-11-21 10:02 , Processed in 0.268490 second(s), 2 queries , Gzip On, Memcache On.